In January–March 2025, the Russian pharmaceutical retail market was 467.9 billion rubles (retail prices, VAT included), up 16.6% from the same period in 2024, according to RNC Pharma’s Pharmaceutical Drug Retail Sales in Russia database. In physical terms, it was 1.29 billion packages, up 2.3% from January–March 2024. In March 2025, around 457 million packages worth 169 billion rubles were sold, up 8% in physical and 22% in monetary terms. The growth rate in rubles is a 27-month high—the market grew at a comparable rate back in November 2024, when the growth rate was 21.5%.

Anti-inflammatory and antirheumatic non-steroids (M01A by the EphMRA classification) accounted for the largest sales in monetary terms—78.7 million packages worth over 22.7 billion rubles were sold, up 10% in packages and 18% in rubles. Nurofen by Reckitt Benckiser was the best-selling brand name in the group, with growth rates of 27% in monetary and 19% in physical terms.

Antivirals excluding anti-HIV (J05B) ranked second—its sales went up 21% in rubles and 11% in packages. A notable example in the group is Ingavirin by Russian Valenta—the sales of the drug rose 20% in monetary and 14% in physical terms.

Nasal preparations for topical use round out the top three with growth rates of 6% in rubles and 1% in packages. The best-selling brand name in the group was Otrivin by GSK—its sales went up 19% in both monetary and physical terms.

The sales of all top groups of drugs, except for expectorants, increased from January–March 2024. Hepatoprotectors and lipotropics had the best growth rates in monetary terms, 24% (or 10% in physical terms. Heptral by Abbott was the best-selling product in the group, with growth rates of 27% in rubles and 19% in packages.

Tab. Top 10 groups of pharmaceutical drugs on the Russian retail market, January–March 2025

* excl. sales of botilinum toxin in aesthetic clinics